NORA JOHNSON SUZANNE M 4

What Happened

• Nora Johnson, a member of Pfizer's Board of Directors, was granted 7,686.539 deferred units (phantom shares) on 2026-04-23. The units were valued at $26.67 each, for a total grant value of $205,000. This was a compensation award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-27 (filed within the two-business-day requirement).
• Grant details: 7,686.539 units @ $26.67 per unit = $205,000 (derivative award).
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1: Each unit represents one phantom share of common stock.
  • F2: Granted under the Pfizer Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
  • F3: Units represent deferred director compensation settled in cash or common stock at the director’s election after retirement from the board.
• Transaction type: Award of deferred/phantom units (derivative), not an exercised option or market trade.

Context

• Deferred phantom units are a form of director compensation tied to Pfizer’s share value but do not represent immediate share ownership; they are settled in cash or stock later (here, upon the director’s retirement, per the plan). Such awards are routine for non-employee directors and reflect compensation rather than a direct market-confidence signal.